SEC Form SC 13G/A filed
$XLRN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2021 | $180.00 | Hold | Jefferies |
| 10/4/2021 | Strong Buy → Market Perform | Raymond James | |
| 10/1/2021 | $180.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/1/2021 | $150.00 → $180.00 | Overweight → Equal-Weight | Barclays |
| 10/1/2021 | $173.00 → $180.00 | Outperform → Market Perform | Cowen & Co. |
| 9/30/2021 | $168.00 → $180.00 | Buy → Neutral | HC Wainwright & Co. |
| 9/30/2021 | $146.00 → $180.00 | Overweight → Neutral | Piper Sandler |
| 9/30/2021 | $148.00 → $180.00 | Market Perform | SVB Leerink |
Fund III will be invested in early-stage therapeutics and healthcare technology companies Qiming Venture Partners USA (Qiming US), a leading US healthcare investment firm, today announced the closing of its third fund, raising $260 million in an oversubscribed fundraise with strong support from new and existing investors. Qiming US will continue to execute on the same strategy as previous funds, deploying Fund III in early-stage therapeutics and healthcare technology companies in the US and EU that aim to improve patient outcomes and address unmet medical needs. "We are incredibly proud of the entrepreneurs and healthcare innovations we have supported in just a few short years, and we are
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the successful completion of the acquisition of Acceleron Pharma Inc. (NASDAQ:XLRN). "This is an important and strategic opportunity for our company to continue growing our cardiovascular portfolio and pipeline, that builds on our long and proud legacy in cardiovascular disease and further bolsters our business development strategy," said Rob Davis, chief executive officer and president, Merck. "Fueled by Acceleron's groundbreaking research, we are excited to explore the opportunities and possibilities ahead to reach even more patients by addressing this critical health need." Acceleron is focused on harn
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, Astros Merger Sub, Inc., for all of the outstanding shares of common stock of Acceleron Pharma Inc. (NASDAQ:XLRN), at a purchase price of $180 per share in cash, without interest and less applicable tax withholding. As of the tender offer expiration at 5:00 p.m., Eastern Time, on Nov. 19, 2021, 38,752,614 shares of common stock of Acceleron were validly tendered and not withdrawn from the tender offer, representing approximately 63.3% of the total number of Acceleron's outstanding shares. All such shares have been accepted for payment
Jefferies initiated coverage of Acceleron Pharma with a rating of Hold and set a new price target of $180.00
Raymond James downgraded Acceleron Pharma from Strong Buy to Market Perform
Morgan Stanley downgraded Acceleron Pharma from Overweight to Equal-Weight and set a new price target of $180.00
4 - ACCELERON PHARMA INC (0001280600) (Issuer)
4 - ACCELERON PHARMA INC (0001280600) (Issuer)
4 - ACCELERON PHARMA INC (0001280600) (Issuer)
For Immediate Release: April 28, 2021 Statement From: Statement Author Leadership Role Acting Commissioner of Food and Drugs - Food and Drug Administration Janet Woodcock M.D. Being transparent about the results of completed clinical trials enables important a
15-12B - ACCELERON PHARMA INC (0001280600) (Filer)
8-K - ACCELERON PHARMA INC (0001280600) (Filer)
25-NSE - ACCELERON PHARMA INC (0001280600) (Subject)
Remains Opposed to Sale of Acceleron to Merck at Current Price and Plans Not to Tender Its Shares Believes Company Has Strong Momentum and Continuing as Standalone Entity is Superior Path to a Transaction at the Proposed Price, Particularly with Major Value Inflection Point Coming from Phase 3 Data Outlines Alternatives by Which Acceleron Could Maximize Shareholder Value as Independent Company, Including by Monetizing Royalties Ready and Willing to Assist with Change in Board Composition to Better Position Company for Go-Forward Strategy Avoro Capital Advisors ("Avoro"), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately
Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY, or 13% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.47 and Non-GAAP EPS of $1.93 Delivers Strong Commercial Performance, Including Opdivo's Return to Growth and Momentum across New Product Portfolio Achieves Significant Regulatory and Clinical Milestones across Product Pipeline Further Strengthens Pipeline through Disciplined Business Development Agreements, including with Agenus and Eisai Adjusts GAAP and Reaffirms Non-GAAP EPS Guidance for 2021 Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2021, which reflect robust product sales, co
SC 13D/A - ACCELERON PHARMA INC (0001280600) (Subject)
SC 13G/A - ACCELERON PHARMA INC (0001280600) (Subject)
SC 13D - ACCELERON PHARMA INC (0001280600) (Subject)